Abstract:Abstract Introduction: In vivo CRISPR screens across multiple murine models of malignancy revealed that loss of interferon gamma (IFN-γ)-mediated sensing predisposes to immune elimination. We assessed the association between damaging mutations in the IFN-γ pathway and clinical outcomes after immune checkpoint inhibition in the Stand Up to Cancer-Mark Foundation non-small cell lung cancer (NSCLC) cohort. Methods: The sensitizing IFN-γ pathway genes were defined as IFNGR1, IFNGR2, JAK1, JAK2, STAT1, IRF1 & IRF9. Damaging mutations (including missense mutations) in any of these genes was considered as loss of pathway activity. We used the best observed response (measured by RECIST v1.1 criteria across time points) to define outcome. Complete and partial response were categorized as responses (R), while stable and progressive disease were categorized as non-responses (NR). The percentage change in target lesions (CTL) was also assessed. Response data was analyzed using additive logistic (LogR) and linear regression (LinR). Overall survival (OS) and progression-free survival (PFS) were analyzed using Cox proportional-hazards models. Three predictor variable groups were established; the final models comprised IFN-γ pathway loss, tumor mutational burden (TMB), programmed death-ligand 1 (PD-L1) tumor proportion score (TPS), prior platinum chemotherapy, age, sex, histological subtype, initial tumor stage, and smoking pack years. Results: 309 patients had evaluable whole-exome sequencing data, treatment with PD-(L)1 inhibitor regimens, and matched radiological responses (121 R [39%], 188 NR [61%]); 306 had matched OS data; 297 had matched PFS data; and 227 had matched CTL data. 27 (7%) patients had damaging mutations in the IFN-γ pathway [IFNGR1 (3); IFNGR2 (1); JAK1 (6); JAK2 (8); STAT1 (3); IRF1 (1); IRF9 (3); and JAK2 & IRF9 (1)]. Significant relationships were observed in univariable models between IFN-γ pathway loss and both response (LogR: OR 0.17, p=2 × 10−4*; LinR: OR 0.70, p=4.8 × 10−4*) and survival (PFS: HR 0.45, p=0.0067*; OS: HR 0.51, p=0.037*). IFN-γ pathway loss is significantly associated with TMB (p=9.7 × 10−8*, Wilcoxon signed rank test). Multivariable models incorporating TMB and PD-L1 TPS confirmed the significance of IFN-γ pathway loss in both response (LogR: OR 0.29, p=0.050*; LinR: OR 0.71, p=0.0052*) and survival (PFS: HR 0.37, p=0.036*; OS: HR 0.27, p=0.030*). These relationships persisted in the final multivariable models (LogR: OR 0.32, p=0.11; LinR: OR 0.69, p=0.012*; PFS: HR 0.39, p=0.068; OS: HR 0.15, p=0.0038*). Random gene sets, of similar total protein coding sequence length, significantly associated with TMB but not with multivariable models of response or survival. Conclusion: In this NSCLC cohort, damaging IFN-γ pathway mutations associate with increased immunotherapy sensitivity, independently of TMB and other co-variates, as evidenced by multiple clinical outcomes. Citation Format: Alexander Azizi, Arvind Ravi, Natalie Vokes, Stephen-John Sammut, Justin Gainor, Gad Getz. Increased immunotherapy sensitivity associated with damaging IFN-gamma pathway mutations in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1169.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Defining the mechanisms of action and resistance to the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain models

Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

IFN-γ Mediates CD4+ T-cell Loss and Impairs Secondary Antitumor Responses after Successful Initial Immunotherapy

Selective Suppression of Melanoma Lacking IFN-γ Pathway by JAK Inhibition Depends on T Cells and Host TNF Signaling

Overcoming Immunotherapy Resistance in Melanoma Defective of IFN-γ Signaling

Functional genomic landscape of T-cell mediated cytotoxicity.

Abstract 1169: Increased immunotherapy sensitivity associated with damaging IFN-gamma pathway mutations in NSCLC

IFNγ-dependent remodelling of the myeloid landscape underlies control of IFNγ-insensitive tumours

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

Understanding the cellular and molecular mechanism of anti-CTLA4 mediated tumor rejection

Identification of essential genes for cancer immunotherapy

CTLA-4 Blockade Increases IFNγ-producing CD4 + ICOS Hi Cells to Shift the Ratio of Effector to Regulatory T Cells in Cancer Patients

Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis

Suppression of Type I Ifn Signaling in Tumors Mediates Resistance to Anti-Pd-1 Treatment That Can Be Overcome by Radiotherapy

A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies

Fc-Dependent Depletion of Tumor-Infiltrating Regulatory T Cells Co-Defines the Efficacy of Anti-Ctla-4 Therapy Against Melanoma

Targeting ULK1 decreases interferon-γ-mediated resistance to immune checkpoint inhibitors.

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma